Experimental drug targets deadly heart rhythm disorder
NCT ID NCT06275893
Summary
This early-stage study is testing whether an experimental drug called IC14 can help control arrhythmogenic cardiomyopathy, a serious heart condition that causes dangerous irregular heartbeats. Five patients who already have implanted defibrillators will receive four intravenous infusions over 12 weeks. Researchers will primarily check if the treatment is safe and measure its effects on inflammation markers and heart rhythms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.